目的 研究表皮生长因子受体EGFR，C-erbB-2原癌基因在乳腺癌中的表达，探讨其与乳腺癌骨髓微小转移间的关系及对乳腺癌患者预后的影响。方法 选择42例乳腺癌患者石蜡固定的组织标本，用SABC免疫组织化学方法检测EGFR，C-erbB-2蛋白。采...目的 研究表皮生长因子受体EGFR，C-erbB-2原癌基因在乳腺癌中的表达，探讨其与乳腺癌骨髓微小转移间的关系及对乳腺癌患者预后的影响。方法 选择42例乳腺癌患者石蜡固定的组织标本，用SABC免疫组织化学方法检测EGFR，C-erbB-2蛋白。采用χ2检验。结果 EGFR阳性42．9％，C-erbB-2阳性31％。EGFR与C-erbB-2两者间无显著关系。随访患者中，EGFR，C-erbB-2阳性与阴性间术后5年生存率有明显差别。结论 EGFR，C-erbB-2表达与乳腺癌骨髓微小转移有密切关系，可以作为判断乳腺癌预后的重要指标。乳腺癌组织中EGFR，C-erbB-2阳性患者预后不良。Objective To investigate the expression of epidermal growth factor receptor and C-erbB-2 proteins in breast cancer, and their relation with micrometastasis in bone marrow.Methods SABC immunocytochemical assay for EGFR and C-erbB-2 proteins were made on paraffin embedded sections. The statistical analyses were performed using chi-square test.Results Overall, 42.9% of the tumors were EGFR positive. C-erbB-2 were positive in 31% of the tumors. The positivlty of both EGFR, C-erbB-2 was significantly correlated with that of micrometastasis in bone marrow. The positivity of EGFR was not related to that of C-erbB-2. The follow-up period was 60 months. The overall survival was worse in patients with EGFR, C-erbB-2 positive tumors than EGFR, C-erbB-2 negative tumors.Conclusion EGFR, C-erbB-2 proteins are significantly related to micrometastasis in bone marrow. Multivariate analyses showt hat both EGFR and C-erbB-2 proteins are two key prognostic factors in breast cancer patients.展开更多
文摘目的 研究表皮生长因子受体EGFR，C-erbB-2原癌基因在乳腺癌中的表达，探讨其与乳腺癌骨髓微小转移间的关系及对乳腺癌患者预后的影响。方法 选择42例乳腺癌患者石蜡固定的组织标本，用SABC免疫组织化学方法检测EGFR，C-erbB-2蛋白。采用χ2检验。结果 EGFR阳性42．9％，C-erbB-2阳性31％。EGFR与C-erbB-2两者间无显著关系。随访患者中，EGFR，C-erbB-2阳性与阴性间术后5年生存率有明显差别。结论 EGFR，C-erbB-2表达与乳腺癌骨髓微小转移有密切关系，可以作为判断乳腺癌预后的重要指标。乳腺癌组织中EGFR，C-erbB-2阳性患者预后不良。Objective To investigate the expression of epidermal growth factor receptor and C-erbB-2 proteins in breast cancer, and their relation with micrometastasis in bone marrow.Methods SABC immunocytochemical assay for EGFR and C-erbB-2 proteins were made on paraffin embedded sections. The statistical analyses were performed using chi-square test.Results Overall, 42.9% of the tumors were EGFR positive. C-erbB-2 were positive in 31% of the tumors. The positivlty of both EGFR, C-erbB-2 was significantly correlated with that of micrometastasis in bone marrow. The positivity of EGFR was not related to that of C-erbB-2. The follow-up period was 60 months. The overall survival was worse in patients with EGFR, C-erbB-2 positive tumors than EGFR, C-erbB-2 negative tumors.Conclusion EGFR, C-erbB-2 proteins are significantly related to micrometastasis in bone marrow. Multivariate analyses showt hat both EGFR and C-erbB-2 proteins are two key prognostic factors in breast cancer patients.
